3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Carcinoma, Hepatocellular
27
Parkinson Disease 4, Autosomal Dominant Lewy Body
24
Neoplasms
14
Melanoma
9
Endometrial Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Non-Small-Cell Lung
7
Thyroid Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Cholangiocarcinoma
6
Stomach Neoplasms
4
Recurrence
4
Carcinoma
4
Biliary Tract Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Lymphoma
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Paraganglioma, Extra-Adrenal
2
Osteosarcoma
2
Neuroendocrine Tumors
2
Lung Neoplasms
2
Liver Neoplasms
2
Glioma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, Hurthle cell
1
Interventions
Ipilimumab
12
tremelimumab
6
durvalumab
6
Nivolumab
6
pembrolizumab
4
Paclitaxel
2
Oxaliplatin
2
Carboplatin
2
Capecitabine
2
Blood Specimen Collection
2
spartalizumab
1
relatlimab
1
lenvatinib
1
folfirinox
1
Vaccines
1
Radiotherapy
1
Radiofrequency Ablation
1
Radiation
1
Opdualag
1
Monophenol Monooxygenase
1
Leucovorin
1
Fluorouracil
1
Docetaxel
1
Cryosurgery
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Diabetes Mellitus, Insulin-Dependent, 12
×
lenvatinib
×
Clear all
NCT04305054
2026-05-28
KEYMAKER-U02
Merck Sharp & Dohme LLC
Phase 1/2
Completed
335 enrolled